The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… ...

Inovio Pharmaceuticals specializes in DNA-based immunotherapies for HPV-related conditions, cancer, and infectious diseases. The company's flagship drug, INO-3107, shows promise for treating recurrent ...

Shares of Inovio Pharmaceuticals Inc. INO shed 3.24% to $1.79 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising ...

Shares of Inovio Pharmaceuticals pulled back by 5.3% during Wednesday’s session. The decline may be attributed to profit-taking, as investors assess renewed focus on respiratory illnesses. See the ...

Inovio Pharmaceuticals (INO) reported a disappointing 3Q25 with a GAAP EPS loss of -$0.87, missing consensus by $0.45 and triggering a 12% stock slide. INO ended the quarter with $50.8 million in cash ...

Inovio (INO) Pharmaceuticals announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock, in an underwritten public offering ...

Shares of Inovio Pharmaceuticals INO jumped 20.6% on Wednesday after the FDA agreed to the company’s rolling submission timeline for the biologics license application (BLA) seeking approval for ...

Shares of Inovio Pharmaceuticals Inc. INO rallied 1.12% to $1.81 Friday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.92 ...